Immuneering Corporation (IMRX)
| Market Cap | 276.26M -28.0% |
| Revenue (ttm) | n/a |
| Net Income | -57.28M |
| EPS | -0.98 |
| Shares Out | 64.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 513,394 |
| Open | 4.360 |
| Previous Close | 4.340 |
| Day's Range | 4.255 - 4.400 |
| 52-Week Range | 3.860 - 9.600 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 17.17 (+302.11%) |
| Est. Earnings | Nov 11, 2026 |
About IMRX
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for IMRX stock is "Strong Buy." The 12-month stock price target is $17.17, which is an increase of 302.11% from the latest price.
News
Immuneering to Present at the ESMO Congress 2026
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno...
Immuneering Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Atebimetinib, a third-generation MEK inhibitor, is in phase III for first-line pancreatic cancer, showing a median OS of 17.3 months and strong tolerability. Its unique mechanism and synergy with mutation-specific RAS inhibitors position it as a promising option in a major unmet need.
Immuneering Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Atebimetinib, a novel MEK inhibitor, shows strong efficacy and tolerability in first-line pancreatic cancer, nearly doubling median overall survival compared to standard care. Ongoing phase III trials and upcoming data updates aim to further validate its differentiated profile.
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the ...
Immuneering to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno...
Immuneering says FDA approval of pancreatic cancer treatment ‘good news’
Immuneering (IMRX) Corporation shared comments following the recent FDA approval of a new second-line pancreatic cancer treatment. “Approval of this new treatment is good news for the subset of pancre...
Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
- For patients with second-line (2L) metastatic pancreatic cancer, today's FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic cancer...
Immuneering initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Immuneering (IMRX) with a Buy rating and $14 price target The firm says the company’s atebimetinib appears capable of delivering substantial pathway inhibition wi...
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on Jun...
Immuneering Earnings release: Q2 2026
Immuneering released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Immuneering Quarterly report: Q2 2026
Immuneering has published its Q2 2026 quarterly earnings report on August 5, 2026.
Immuneering publishes preclinical data on atebimetinib in Cancer Research
Immuneering (IMRX) announced the publication of new findings in Cancer Research, a journal of the American Association for Cancer Research, characterizing the mechanism and preclinical activity of ate...
Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constraine...
Immuneering Corporation Announces Grants of Inducement Awards
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously ...
Immuneering initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Immuneering (IMRX) with an Overweight rating. Immuneering is developing a new class of deep cyclic inhibitors, with its lead MEK inhibitor atebimetinib advancin...
Immuneering appoints Andrew Gengos as CFO
Immuneering (IMRX) announced the appointment of Andrew Gengos as CFO, effective July 16. Gengos most recently served as CFO and head of corporate development at Terns Pharmaceuticals. At Immuneering, ...
Immuneering Appoints Andrew Gengos as Chief Financial Officer
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Imm...
Immuneering Transcript: AGM 2026
The meeting covered director elections and auditor ratification, with both proposals approved. No questions were raised by stockholders, and final vote results will be published in a Form 8-K filing.
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endp...
Immuneering announces updated clinical data from atebimetinib combination trial
Immuneering (IMRX) announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic d...
Immuneering Transcript: Study result
Phase II-A data for atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer show a median overall survival of 17.3 months with favorable tolerability and high rates of weight stability. The phase III MAPKeeper 301 trial is now recruiting, and the company is financially positioned to fund operations into 2029.
Immuneering Press release: Study result
Immuneering issued a press release on June 1, 2026, disclosing material business information to investors.
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering reports Q1 EPS (21c), consensus (25c)
“We are excited that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in our Phase 2a clinical trial will be reported in an oral…